| 13 -0.99 (-7.08%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 18 | 1-year : | 21.71 |
| Resists | First : | 15.41 | Second : | 18.59 |
| Pivot price | 15.05  |
|||
| Supports | First : | 10.28 | Second : | 8.56 |
| MAs | MA(5) : | 14.11 |
MA(20) : | 14.3 |
| MA(100) : | 20.26 |
MA(250) : | 21.88 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 18.4 |
D(3) : | 33.8 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 65.8 | Low : | 2.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VOR ] has closed above bottom band by 17.4%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.84 - 14.92 | 14.92 - 14.99 |
| Low: | 12.67 - 12.78 | 12.78 - 12.86 |
| Close: | 12.85 - 13 | 13 - 13.13 |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Thu, 29 Jan 2026
VOR Stock Unaffected by Selling Stockholders' Actions - GuruFocus
Wed, 21 Jan 2026
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Fri, 09 Jan 2026
Citigroup Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation - Nasdaq
Wed, 10 Dec 2025
Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR) - Seeking Alpha
Tue, 09 Dec 2025
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target - Investing.com
Tue, 09 Dec 2025
JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 43.8 (%) |
| Shares Short | 2,270 (K) |
| Shares Short P.Month | 226 (K) |
| EPS | -386.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -246.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -144.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -144 (M) |
| Levered Free Cash Flow | -183 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|